Increased versican content is associated with tendinosis pathology and microvascular hyperplasia in the patellar tendon of athletes with jumper’s knee

Alexander Scott1, Øystein Lian2,3, Clive C Roberts4, Jill L Cook5, Christopher J. Handley6, Roald Bahr2, Tom Samiric6, Mirna Z. Ilic6, John Parkinson6, David A Hart7, Vincent Duronio1, Karim M Khan1,8,9

1 Department of Medicine, University of British Columbia, Vancouver, Canada
2 Oslo Sport Trauma Research Center, Department of Sports Medicine, Norwegian School of Sport Sciences, Oslo, Norway
3 Kristiansund Hospital, Kristiansund, Norway
4 Centre for Blood Research and Faculty of Dentistry, University of British Columbia, Vancouver, Canada
5 Faculty of Health Sciences, La Trobe University, Melbourne, Australia
6 School of Human Biosciences, La Trobe University, Melbourne, Australia
7 Departments of Surgery, Microbiology & Infectious Diseases and Medicine, University of Calgary, Calgary, Alberta, Canada
8 Department of Family Practice, University of British Columbia, Vancouver, Canada
9 Centre for Hip Health, Vancouver Coastal Health and Research Institute

Running head: Excess versican in human patellar tendinosis
ABSTRACT

Objective: Expansion of the extracellular matrix is a prominent but poorly characterized feature of tendinosis pathology. We aimed to characterize the extent and distribution of the large aggregating proteoglycan versican in patients with patellar tendinosis.

Methods: Tendon was obtained from tendinopathy patients undergoing debridement of the patellar tendon and from controls undergoing intramedullary tibial nailing. Versican content was investigated by Western blotting and immunohistochemistry. Microvessel thickness and density were determined using computer-assisted image analysis. Markers for smooth muscle (α-SMA), endothelial cells (CD31) and proliferating cells (Ki67) were examined immunohistochemically.

Results: Western blot analysis showed increased versican content in patellar tendon biopsies from patients compared to controls. Immunohistochemical staining demonstrated that versican content was elevated in the proximal patellar tendon of tendinosis patients (p=0.042). Versican content appeared enriched in regions of fibrocartilage metaplasia and fibroblast proliferation, as well as in the perivascular matrix of proliferating microvessels, and within the media and intima of arterioles. Microvessel density was higher in patients compared to controls.

Conclusions: Elevated versican deposition is a prominent feature of patellar tendinosis. Because this molecule is not only a component of normal fibrocartilagenous matrices, but is also implicated in a variety of soft tissue pathologies, future studies should further detail both pathological and adaptive roles of versican in tendons.
INTRODUCTION

Tendinopathy is a common source of chronic musculoskeletal pain (Hazleman et al. 2004). The histology of tendinosis – the underlying pathology in many cases of tendinopathy - is well described and certain histopathological features of tendinosis appear to be consistent across tendons (Khan et al. 1999), but the molecular changes in tendon composition have been investigated less extensively. Imaging abnormalities include hypoechoic areas on greyscale ultrasound and high signal on magnetic resonance imaging (MRI), corresponding to an increase in glycosaminoglycans (Cook et al. 2000). Cross-sectional studies of tendon from competitive athletes have demonstrated that such abnormal tendon morphology on imaging – even when not associated with symptoms -- is associated with a 4.2 times greater risk of developing into symptomatic tendinopathy compared with a sonographically normal tendon (Cook et al. 2000). Thus, changes in the extracellular matrix may represent an important aspect of the tendinosis pathology.

Unlike osteoarthritis which is characterized by a loss of glycosaminoglycan and decreased DNA content, biochemical assays of tendinosis have demonstrated an increased presence of glycosaminoglycan and DNA. Chondroitin sulphate is the major glycosaminoglycan in tendinosis tissue and the accompanying increase in DNA content has been primarily attributed to fibroblasts and vascular cells (endothelial and smooth muscle cells) (Khan et al. 1996; Fenwick et al. 2002). Therefore, the excessive chondroitin sulphate found in biochemical assays of tendinosis could be produced by resident fibroblasts (tenocytes) or by vascular cells, or both (Riley 2005). Furthermore,
the core proteins to which the glycosaminoglycan is likely bound have not yet been examined to our knowledge.

Versican is the most abundant of the large chondroitin sulphate proteoglycans in tendon (Yoon and Halper 2005). Immunohistochemical studies of normal tendon and of collagenase-digested tenocyte arrays have found versican in the endotendon around vessels, and in the pericellular matrix around tenocytes (Bode-Lesniewska et al. 1996; Ritty et al. 2003). In an experimental model of subfailure ligament injury, versican mRNA in resident fibroblasts was reported to be acutely upregulated (Provenzano et al. 2005). This finding may be consistent with versican’s role in creating a hydrated, anti-adhesive matrix that promotes cellular proliferation and migration following injury (Kinsella et al. 2004). Versican is also upregulated in bovine tendon by in vitro compressive loading (Robbins et al. 1997), a mechanical stimulus which has been hypothesized to occur at the inferior patellar pole during loaded knee flexion (Almekinders et al. 2003; Hamilton and Purdam 2004). Thus, both injury or altered mechanical loading could lead to distinct patterns of increased versican synthesis in tendon, and the distribution of versican in tendons may give insight into the underlying mechanisms.

Therefore, the aim of the current study was to characterize the extent and distribution of versican in the patellar tendon of athletes presenting with tendinosis. We hypothesized that versican would be present in excess in patellar tendinosis, and that it would be
distributed in the extracellular matrix surrounding tenocytes, endothelial cells, and/or smooth muscle-containing cells.

METHODS

Subjects

Tendon tissue was obtained from control participants (n=10) and from patients with documented patellar tendinosis (n=21). These patients (18 males and 3 females) were athletes who had experienced pain for longer than 3 months and were unable to participate in sport at their pre-injury level. The average Victorian Institute of Sports Assessment (VISA) score for patients was 42 (15-65) indicating significant functional limitation (0=very poor function and 100=perfect function and no pain) (Visentini et al. 1998). All patients in the present study also had MRI abnormalities at the proximal aspect of the patellar tendon confirmed by a board-certified musculoskeletal radiologist and a specialist orthopaedic surgeon. The control group (7 males and 3 females) was selected from patients undergoing intramedullary nailing for low-energy tibia fractures and who had no current or previous knee pain. Patients or controls had none of the following; previous surgical treatment in or around the knee, corticosteroid injections in or around the knee, serious traumatic injury affecting the knee, or any rheumatic or degenerative knee condition. Average age of subjects was 30 years (24-34 years, n=21) in the patient group and 29 years (19-43 years, n=10) in controls. All subjects gave their written, informed consent. The study was approved by the local Committees for Research Ethics in Australia, Norway and Canada.
**Biopsy procedure**

The surgical technique and biopsy handling was identical in the two groups. Biopsies were taken from the proximal bone-tendon junction, and the tendon tissue was excised using a full thickness wedge-shaped incision, widest at the patellar pole (1 cm) and narrowing distally (2-3 cm in length). Biopsies were either immediately frozen in liquid nitrogen and stored at -80°, or chemically fixed in Zamboni’s solution for 4 to 24 h and then washed in 0.1 M phosphate-buffered NaCl, pH 7.2, with 15% sucrose (weight/volume) (PBS) and 0.1% natriumazide. After fixation, the biopsies were stored in PBS at 4°C, dehydrated, paraffin embedded and serially sectioned at 5 µm thickness.

We applied Bonar’s classification system (Khan et al. 1999) to confirm the presence of tendinosis in patients, and its absence in controls, using tendon sections stained with Alcian blue and haematoxylin & eosin (H&E). Distinct features of tendinosis (fibrocartilage metaplasia, neovascularization, fibroblastic hypercellularity) were independently identified by two investigators (AS, JLC) blinded to group. The inter-rater reliability for identifying these features was 100%. Patient biopsies that yielded tissue sections at least 1cm² in size (10 of 21 biopsies) were used for more extensive qualitative observations regarding the relation of versican expression to features of tendinosis.

**Detection and quantification of versican in tissue sections**

*Western Blot methodology*

Tendon samples were extracted from samples of tendon with 4M guanidium chloride and 50 mM sodium acetate buffer (50 mM sodium acetate, 100 mM disodium sulphate; pH 5.8) containing proteinase inhibitors for 72 hours at 4°C. The protease inhibitor cocktail
was prepared as a 10X concentrate and added to the buffered guanidine hydrochloride solution to give final concentration of 8 mg/l soybean trypsin inhibitor (SBTI), 0.1 M aminohexanoic acid, 0.01 M ethylenediaminetetra-acetic acid (EDTA), 1.0 mM benzamidine hydrochloride, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 2.0 mM iodoacetic acid and 0.02 % (w/v) sodium azide. The proteoglycans present in the extract were isolated by ion-exchange chromatography on Q-Sepharose, deglycosylated with chondroitinase ABC and keratanase, and separated by SDS-polyacrylamide electrophoresis as previously described (Samiric et al. 2004). Handling and processing of patient and control biopsy material was identical. The gels were then analysed by Western blotting using the antibodies LF99 (a generous gift of Dr Larry Fisher, NIH) and 2B1 (Seikagaku, Japan) to versican (Bernstein et al. 1995). The LF99 antibody recognizes an epitope at the N-terminal region which is cleaved during versican maturation, and therefore represents newly synthesized proteoglycan. The 2B1 antibody was originally raised against proteoglycans extracted from a human yolk sac tumour, and was later identified to specifically recognize an epitope close to the C-terminal domain in the versican core protein (Isogai et al. 1996). Samples equivalent to 2µg wet weight of tissue were applied to each well.

Quantitative immunohistochemistry

The distribution of versican was examined in tissue sections using the 2B1 antibody followed by a commercially available avidin-biotin-HRP visualization system (Vector Labs). Stained tissue sections were systematically scanned at 20x magnification by a technician who was unaware of the labeling code using the BLISS microscope workstation (Bacus Laboratories, Lombard, U.S.A.). Image Pro Plus (version 4.5.1.22
from Media Cybernetics, San Diego, California, USA) was used to highlight positive
DAB end-reaction product using the same RGB threshold file for all sections. Values are
expressed as the average number of positive pixels per field.

Labeling of proliferating cells and vascular cell types

Proliferation of endothelial and smooth muscle cells are key events in angiogenesis,
which is an important feature of tendinosis (Kristoffersen et al. 2005). Therefore,
monoclonal antibodies against markers for endothelial cells (CD31; DAKO JC70A),
smooth muscle actin (α-SMA; Biomeda 1A4), and proliferating cells (Ki67; BD
Pharmingen B56) were used to label cell types in normal and patellar tendinosis tissue.
CD31 (platelet endothelial cell adhesion molecule) has been commonly used to identify
microvascular endothelial cells (Biberthaler et al. 2003). α-SMA has been shown to
identify the contractile cytoskeleton in the media of arterioles, as well as pericytes and
myofibroblasts (Skalli et al. 1986, 1989; Darby et al. 1990). Ki67 is a nuclear protein
expressed in proliferating cells, with peak expression during M phase (Landberg et al.
1990).

Determination of microvessel parameters

Microvessels (defined here as vessels with diameter <50 μm or smaller) from the 10 most
proximal viewing fields (40x objective, 0.35mm² total area) were outlined using
digitized, systematically scanned micrographs of H&E sections. All individual vessel
profiles were manually traced in Image Pro Plus and counted with the digital counting
tool. Vessel density was defined as the number of profiles per mm². Vessel thickness
and lumen were determined by measuring vessel profiles in the transverse plane.
Thickness was defined by the external borders of the adventitia, whereas the lumen diameter was defined by the internal borders of the intima. To obtain a sufficient number of vessels for analysis of thickness and lumen (n=303), both circular and oblique vessel profiles were included as long as the plane of section passed completely through the vessel; diameters were thus obtained using the least diameter method, which minimizes measurement error due to oblique sectioning (Clarkson et al. 1980).

**Statistical analysis**

To compare the amount of versican immunostaining in control and patient samples, the average number of positive pixels was subjected to a *t*-test with significance predetermined at $\alpha=0.05$, after ensuring the data were normally distributed and did not violate the assumption of equal variance (Levene’s test). Results are expressed as mean $\pm$ SD. Vessel density was compared in the same way. Vessel diameters were not normally distributed, and the distribution appeared to differ between patients and controls; therefore the non-parametric Kolmogorov-Smirnov test was used to test the hypothesis that the distributions were drawn from different populations. Analysis was carried out using SPSS version 13.0 (SPSS Inc., Chicago, U.S.A.).

**RESULTS**

**Comparison of versican expression in normal tendon and tendinosis**

Western blot analysis of proteoglycan samples extracted from patellar tendon samples demonstrated that in pathological tissue there were clearly increased levels of versican present in pathological tissue (Figure 1). Most of the versican labeled by the 2B1 antibody appeared to be catabolic products of the proteoglycan (Samiric et al. 2004).
Labeling with the LF99 antibody was prominent in gels obtained from patient samples but was barely detectable in normal tendon, and appeared to preferentially identify a high molecular weight form of versican.

Semi-quantitative immunohistochemistry independently confirmed that versican was present in both normal and pathological tendon, but was significantly increased in patients (2.63 x 10^5 ± 9.0 x 10^4) compared to controls (1.97 x 10^5 ± 6.0 x 10^4, p=0.042).

**Versican distribution in patellar tendinosis – qualitative observations**

Tendons from patients with patellar tendinosis demonstrated three main patterns of versican expression (Figure 2). A proximal-distal pattern of these tendinosis features could be detected in 9 of the 10 patient biopsies which had sufficient tissue for extensive qualitative observation (as described in Methods). In the most proximal part of the tendon (Zone 1), there were prominent regions of fibrocartilage. These regions extended into to the tendon proper up to several millimeters in length and width. In Zone 1, versican was more prominent in tendinosis tissue than in control tissue in the vicinity of more rounded, chondrocytic-appearing tenocytes, sometimes in alternating layers reminiscent of classic descriptions of fibrocartilage. Bordering this zone distally in all cases was a region of vascular hyperplasia (Zone 2) and endothelial proliferation, in which versican was also enriched (Figure 2). Moving distally, Zone 3 was characterized primarily by increased tenocyte density but otherwise normal tendon structure (Figure 2). In these regions, a greater quantity of versican was detected which was distributed evenly throughout the extracellular matrix of the tendon proper. There were generally no focal increases in versican in Zone 3. Finally, large regions of the anterior and distal
patellar tendon in patients with tendinosis were frequently normal and demonstrated no general or focal increase in versican (Figure 2). As in uninjured tendon from control samples, tendon from patellar tendinosis patients contained versican predominantly around microvessels in the endotendon running longitudinally with the principal line of action of the tendon (Bode-Lesniewska; Dours-Zimmermann et al. 1996).

**Association of versican with vascular hyperplasia**

In the hypervascular region, versican formed an expanded glycosaminoglycan-rich matrix penetrated by CD31+ microvessels exhibiting positive Ki67 nuclear labeling in the intima (Figure 3A-C). These microvessels were predominantly arterioles (Figure 3). In microvessels from both normal and tendinosis samples, versican expression was typically complementary to \( \alpha \)-SMA (i.e. absent from the intima media) (Figure 3D,E). However, in some larger arterioles of tendinosis biopsies, versican was present in association with medial and/or intimal hyperplasia (Figure 4), giving the vessel walls an irregular, thickened appearance. In patellar tendinosis tissue samples, \( \alpha \)-SMA-positive fibroblasts (i.e. myofibroblasts) were present in areas of versican-rich tissue, often adjacent to proliferating microvessels, (Figure 5), but this was not the case in normal tendon.

**Quantitation of microvessel density and thickness**

Vascular density was \( 5.6 \pm 9.7 \) vessels per mm\(^2\) in controls, and \( 15.6 \pm 16.7 \) vessels per mm\(^2\) in patients (p=0.026). The distribution of vessel diameters was significantly different in patients (K-S z-score-1.423, p=0.035) (Figure 6) due to an increased presence
of small diameter microvessels (capillaries, venules and arterioles). The distribution of lumen diameters was not different in patient and control samples.

**DISCUSSION**

The major novel finding of this study is that elevations in versican levels contribute to the increased extracellular matrix volume in symptomatic patellar tendinosis. Versican expression was associated with distinct regions of fibrocartilage, hypervascularity, hypercellularity, as well as morphologically normal tendon. Thus, several distinct cell populations and processes appear to contribute to the expression of versican in the patellar tendon with features of tendinosis. This finding extends previous work which demonstrates increased expression of aggrecan and biglycan mRNA in tendinosis lesions (Corps et al. 2006).

Turning first to the zone of fibrocartilage at the inferior pole of the patellar tendon in patient samples (Zone 1), versican was more prominent in the matrix surrounding rounded, chondrocytic cells. Fibrocartilage tends to develop within areas of tendon (distinct from the enthesis) that are subjected to compression or shear, for example at the deep surface of wrap-around tendons such as the supraspinatus or tibialis posterior. However, fibrocartilage metaplasia is also sometimes observed as a pathological dysregulation of cell phenotype, for example in scar tissue (Boor and Ferrans 1985).

Directly adjacent to the region of chondroid metaplasia, a zone of hypervascularity (Zone 2) was consistently observed in patient samples. This was characterized by increased versican expression both in the perivascular matrix and within the vessel walls. This
proximal-distal pattern of fibrocartilage bordered by vascular tissue has been noted previously in the supraspinatus tendon. Fukuda and co-workers examined en-bloc sections of full thickness rotator cuff tears and reported chondroid metaplasia in the proximal remnant of the tendon, whereas the distal torn end was characterized by hypervascular granulation tissue (Fukuda et al. 1990). This is consistent with a hypothesis that fibrocartilage metaplasia may initially develop as an adaptive response to compression under the acromion, but that this adaptation weakens the tendon’s ability to withstand tensile loads, thereby leading to microtears adjacent to the site of fibrocartilage formation. A similar process has been postulated for the tibialis posterior where it is compressed by the medial malleolus (Petersen et al. 2004). These data will therefore be of interest to those who have hypothesized that patellar tendinopathy may have a compressive etiology (Almekinders et al. 2003; Hamilton and Purdam 2004).

Versican was increased in association with vessels in two overlapping patterns. First, and most commonly, there were often dense beds of capillaries and/or arterioles, and the entire region demonstrated excess staining for versican. Proliferating endothelial and smooth muscle cells could be identified in these regions. This pattern is consistent with versican’s role in facilitating proliferation and migration in angiogenesis. The second abnormality was the increased presence of versican in association with intimal and medial hyperplasia of arterioles. We have recently documented increased vascular endothelial growth factor (VEGF) expression by endothelial cells in patellar tendinosis tissue (AS, VD, DAH, KK, unpublished observations). In addition to causing endothelial cells to proliferate, VEGF has been reported to upregulate their expression of versican.
Taken together, these findings suggest a possible causal link between the two findings and a potential role of VEGF in causing or perpetuating the increased versican expression in Zone 2.

Neovessels were occasionally seen in proximity to versican-rich tissue populated by myofibroblasts (α-SMA positive fibroblasts). The presence of myofibroblasts is in keeping with prior studies of tendinosis (Khan et al. 1996) and of other healing soft tissues (Schmitt-Graff et al. 1994), and their association with versican confirms the importance of this proteoglycan in soft-tissue repair and remodeling (Roberts 1995). The factors leading to increased versican expression in healing wounds may include hypoxia (leading to hypoxia-induced-factor-1-α and VEGF expression), cytokines including transforming growth factor-β and PDGF-A and –B (Evanko et al. 1998, 2001; Nikitovic et al. 2006), and compressive or tensile loads (Mao et al. 1998; Grande-Allen et al. 2004; Milz et al. 2005).

A third zone of versican expression was typically seen distal and/or superficial to Zones 1 and 2, and this was characterized by a relatively even elevation in versican levels in association with increased tenocyte density. This could be interpreted as evidence of adaptation. In animals and in humans, exercise can induce adaptive improvements in the material properties of the tendon, including increased stiffness and cross-sectional area (Woo et al. 1980; Kjaer 2004; Yoon and Halper 2005). Chondroitin sulphate content is correspondingly increased in animals subjected to treadmill running vs. sedentary controls (Woo;Ritter et al. 1980; Banes et al. 1999; Kjaer 2004; Yoon and Halper 2005).
Conversely, the increased versican in Zone 3 could still represent a secondary effect due to diffusion of cytokines from adjacent areas.

In the current study, Western blot analysis demonstrated that versican content in patient samples consisted both of newly synthesized, high molecular weight forms, as well as lower weight catabolic products. The regulation of versican expression and turnover is complex and includes alternate splicing of mRNA from the versican gene to generate at least three possible isoforms (Rahmani et al. 2006). Versican degradation involves proteolytic cleavage into distinct entities, and regulation of its catabolism by aggrecanases and matrix metalloproteases, and by their endogenous inhibitors (Kinsella et al. 2004; Rahmani et al. 2006). Future studies should therefore examine these regulatory processes in relation to the development of tendinosis pathology.

In this study, we did not examine the distribution of other potentially relevant components of the extracellular matrix (e.g. aggrecan, biglycan, decorin, lumican, collagens, fibronectin, hyaluronan). In particular, aggrecan is likely to contribute to the regions of fibrocartilagenous metaplasia observed here (Milz et al. 2005). Aggrecan mRNA levels have been reported to be increased in Achilles tendinosis (Corps et al. 2006) and in the ruptured supraspinatus (Lo et al. 2005) whereas versican levels were unchanged compared to controls (Corps et al. 2006). The discrepancy between findings at the protein and mRNA levels in these studies is consistent with a report from cartilage showing that versican protein can remain in the matrix long after mRNA levels have declined (Matsumoto et al. 2006). The complex regulation of versican and other matrix
molecules in the development and progression of tendinosis clearly requires further research.

In summary, we found that versican is present at elevated levels in human patellar tendinopathy, and the increased versican was enriched in distinct regions of the tendon tissue, specifically in areas of fibrocartilage, those with fibroblast proliferation, as well as in the perivascular matrix of proliferating microvessels and within the media and intima of arterioles. We conclude that future studies should address both pathological and adaptive mechanisms underlying the upregulation of versican in the tendon proper and the vascular matrix to better understand the basis and consequences of the elevated protein levels detected in the present studies.

**PERSPECTIVE**

The current study deepens our understanding of patellar tendinosis and the clinical rationale for its treatment. Formerly known as “tendinitis,” a lack of knowledge regarding the underlying pathological processes has hampered the development of effective treatments (Maffulli et al. 1998; Kjaer 2004; Riley 2004). In laboratory studies, the transformation of normal, tensile tendon to fibrocartilage, and vice versa, is related to the dynamic balance of compressive, shear, and tensile forces experienced by tenocytes at specific regions in the tendon (Robbins et al. 1997; Malaviya et al. 2000; Milz et al. 2005). Tensile (eccentric) loading of the patellar tendon using a decline board gives superior results to standard knee flexion exercises in the treatment of patellar tendinosis (Young et al. 2005) and this clinical success has been suggested to result from increased
tensile vs. compressive loading of tenocytes in the posterior, proximal tendon with the
decline board (Young et al. 2005). Therefore, appropriate tensile loads delivered in such
a way as to minimize compression may therefore be able to reverse the process of
fibrocartilage metaplasia in the patellar tendon. Future developments in imaging
technology may allow the dynamic visualization of versican and other matrix proteins in
tendinopathy patients, and thus allow a direct assessment of the molecular response to
rehabilitation.

ACKNOWLEDGEMENTS

This work was funded by grants from the Canadian Institutes of Health Research (CIHR;
MOP-77551) and the Worker’s Compensation Board of British Columbia (grant RS0203-
DG-13). The Oslo Sports Trauma Research Center has been established at the Norwegian
University of Sport & Physical Education through generous grants from the Royal
Norwegian Ministry of Culture, the Norwegian Olympic Committee & Confederation of
Sport, Norsk Tipping, and Pfizer. Mr Scott is recipient of a CIHR Post-Doctoral
Fellowship. Dr Hart is the Calgary Foundation-Grace Glaum Professor in Arthritis
Research and supported by IGH of CIHR. Dr Duronio is the recipient of a Michael
Smith Foundation for Health Research Senior Scholar Award. Dr Khan is recipient of a
CIHR New Investigator Award.

REFERENCES

Almekinders LC, Weinhold PS and Maffulli N. Compression etiology in tendinopathy.


Visentini PJ, Khan KM, Cook JL, Kiss ZS, Harcourt PR and Wark JD. The VISA score: an index of severity of symptoms in patients with jumper's knee (patellar


FIGURE CAPTIONS

Figure 1. Detection of versican in normal and pathological tendon. Western blots of purified tendon proteoglycan extracts (~2ug/lane) were probed with 2B1 (versican C-terminal domain) or LF-99 (N-terminal domain). Lanes represent normal (N) and pathological (P) human patellar tendon samples. Molecular weights are shown in kDa. Similar results were obtained in gels from 5 different patients.

Figure 2. Representative micrographs demonstrating zones of versican deposition in association with specific features of tendinosis pathology; MRI from a jumper’s knee patient is shown for orientation. Zone 1 contains banded distribution of versican (brown staining) in association with chondrocytic cells (Haematoxylin counterstain), bordered distally by microvascular hyperplasia (Zone 2). Zone 2 is interspersed and bordered by tenocyte hypercellularity and a generalized increase in versican content (Zone 3). In surrounding normal tendon versican staining is fainter and is localized to the endotendon. Scale bar on micrographs = 50 microns, on MRI = 1cm.

Figure 3. Association of versican with vascular proliferation A: Diffuse versican labeling (brown) around an abnormally dense capillary bed within the tendon proper, with more intense labeling directly adjacent to the vessels (arrow). B: CD31 labeling endothelial cells serial to A. C: Higher power view of the same region showing Ki67 labeling of endothelial cells in the microvascular walls. D: Intense versican labeling (asterisk) in a region of arteriolar proliferation. E: Serial to D, confirming the presence of α-SMA (brown) in the intima media. Scale bars = 50 microns.

Figure 4. Versican distribution in arterioles from normal tendon and tendinosis tissue. A: Normal arteriole – versican is localized to the surrounding connective tissue, and to a
single layer of endothelial cells (tunica intima). B: Abnormal arteriole – versican surrounds an irregularly thickened endothelial layer and extends into the smooth muscle layer (tunica media), and is also markedly increased in the outer layers. Scale bar = 50 microns.

**Figure 5.** Association of versican with microvascular hyperplasia and myofibroblasts.

A: Versican in association with an abnormal microvascular bed (arrow), and remodeling tissue (asterisk). B: CD31 confirms that the upper structure is vascular, whereas the lower structure is not. C: Intensely labeling of α-SMA in the vascular structure indicating arterioles. α-SMA is also positive in scattered myofibroblasts in the adjacent remodeling area (rectangle). D: Higher power view of rectangular area in C. Scale bars = 50 microns.

**Figure 6.** Quantitation of vessel diameters in the proximal 0.35mm² of the patellar tendon. Morphometric analysis of microvessels demonstrates increased presence of predominantly small (<40 microns) microvessels in patellar tendinosis.
Figure 1 – see attached slide

Figure 2
Figure 3
Figure 6

A

B

Vessel diameter (microns)

Lumen diameter (microns)

Frequency

Controls

Patients